Macro Challenges Make Calls On Newly Resilient Medtechs

Health Care Transition Accelerates And Sustainability Compliance Is Demanding Attention

Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.

sustainability
• Source: Shutterstock

For medtechs, 2022 will be remembered as one of the most challenging years the industry has seen in decades. The COVID-19 pandemic continued to impact operations for much of the year – especially in China – and disrupted supply chains. In addition, soaring inflation and rising interest rates combined to test the industry’s resilience and drag a big shadow over the global economic outlook.

That was how the ostomy and wound care products company Coloplast Ltd. described the events of 2021-2022. But these...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ESG

RESILIENCE Initiative Navigates The World Of Making Medicines Through VR Technology

 

The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.

Cracking Through ‘The Bamboo Ceiling’: East Asians Reach For Pharma Leadership

 
• By 

Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.

Infographic: Analyzing The Gap In Women’s Health Care

 

Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.

Growing Calls For Labelling Changes With Obesity Patients In Mind

 
• By 

Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By 

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.